<\/p>\n
MIMETAS, a leader in human-relevant organ-on-a-chip models, has opened their Phenotypic Screening Center. The centre facilitates large-scale screening campaigns on Organ-on-a-Chip models, a powerful technology that improves the human physiological relevance of cultured tissues by utilizing microfluidic techniques. In contrast to other Organ-on-a-Chip platforms, the MIMETAS OrganoPlate technology offers the scalability and the throughput needed for drug discovery studies.<\/p>\n
The new screening centre is the first energy-neutral laboratory building in the Netherlands. It is located in the new head office of MIMETAS in Oegstgeest, the largest life sciences cluster in The Netherlands.<\/p>\n
\u201cWe are very proud to open up this new centre,\u201d\u00a0said Jos Joore, CEO of MIMETAS.\u00a0\u201cOur new Phenotypic Screening Center facilitates high-throughput organ-on-a-chip screening combined with high-content imaging and machine learning data analysis to identify drug candidates for today\u2019s unmet medical needs. Our customers understand that human-relevant disease models should be at the basis of every drug discovery effort. Moreover, these cutting-edge technologies stimulate the creativity and purpose of our scientists to make a difference in the lives of patients.\u201d<\/p>\n